AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market
HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.
Eli Lilly and Company cut the prices of its weight-loss drug Zepbound, available in single-dose vials, in a bid to end compounding companies from.
HQ Team November 8, 2024: The rise of weight loss medications such as Ozempic (semaglutide) and Wegovy has sparked significant interest and usage.
Overdose of weight-loss drugs and dosing errors by patients and healthcare providers have led to adverse events, including hospitalisation, the USFDA warned.
HQ Team December 22, 2023: The FDA has seized “thousands of units” of counterfeit weight-loss injection Ozempic which have no information about the.
HQ Team October 11, 2023: Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people.